**Specifications Table**TableSubject areaCardiovascular diseasesMore specific subject areaGenetic predisposition to cardiovascular diseaseType of dataTablesHow data was acquiredPyrosequencing, clinical data, biochemical analysisData formatAnalysedExperimental factorsNot applicableExperimental featuresMitochondrial mutations m.1555A\>G, m.3256C\>T, m.3336T\>C, m.5178C\>A, m.12315G\>A, m.13513G\>A, m.14459G\>A, m.14846G\>A, m.15059G\>A, m.652insG were determined using pyrosequencing technology, and their association with CVD was analysedData source locationRostov-on-Don, RussiaMoscow, RussiaVillahermosa, MexicoData accessibilityData are provided in this article

**Value of the data**•The study shows that in genetically and clinically diverse populations, Russian and Mexican ones, the mutations of the mitochondrial genome are differently related to cardiovascular disease.•In samples from Russian population, mitochondrial heteroplasmy level of m.5178C\>A and m.14459G\>A were significantly higher in men and women with CVD, respectively. In samples from Mexican population, heteroplasmy level of these mutations was significantly higher in CVD-free study participants. More, in Mexican population, heteroplasmy levels of m.13513G\>A and m.652insG were associated with CVD in males, and m.652insG-- in females. Higher level of heteroplasmy of mutations m.3336T\>C, m.5178C\>A, m.14459G\>A, m.14846G\>A and m.1555A\>G was demonstrated in healthy men, and that of m.3256C\>T, m.3336T\>C, and m.14459G\>A -- in healthy women.•Estimation of the associations of as much as possible mitochondrial mutations with risk factors and clinical signs of coronary heart disease and atherosclerosis provides an important source for further investigation of the role of mitochondrial heteroplasmy level in the development of cardiovascular pathology.

1. Data {#s0005}
=======

Clinical and laboratory characteristics of Russian and Mexican study participants are presented in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}.Table 1Characteristic of Russian study participants.Table 1VariableMenWomenHealthyCVD*p*HealthyCVD*p*Age, years62.8(10.5)61.6(9.0).63062.2(8.5)62.5(7.6).926BMI, kg/m^2^26.3(4.0)27.6(4.3).27826.1(5.9)27.1(6.3).656SBP, mm Hg142(18)138(14).358133(15)128(11).324DBP, mm Hg84(12)82(11).49982(9)77(7).258Smoking, %1115.68449.108Diabetes, %915.51479.581MI, %05.79100.853Total cholesterol, mg/dL233.9(47.9)227.8(50.2).642254.3(51.4)257.5(51.3).863HDL, mg/dL61.6(15.7)57.2(12.8).27171.6(14.9)75.7(14.1).438LDL, mg/dL147.1(41.6)138.7(48.7).480160.8(46.1)153.9(47.2).677TG, mg/dL125.9(55.5)159.5(102.7).092109.1(51.1)139.3(50.8).105[^1]Table 2Characteristic of Mexican study participants.Table 2VariableMenWomenHealthCVD*p*HealthCVD*p*Age, years58.6(11.3)61.5(10.4).21960.5(10.1)63.8(8.4).217BMI, kg/m^2^30.0(4.9)28.5(6.5).24230.8(4.6)31.0(6.7).900SBP, mm Hg127(21)124(16).394136(22)135(20).888DBP, mm Hg78(11)75(9).13777(8)73(9).137Smoking, %4456.2812038.160Diabetes, %1951.002[\*](#tbl2fnStar){ref-type="table-fn"}3050.144MI, %035\<.001[\*](#tbl2fnStar){ref-type="table-fn"}021.008[\*](#tbl2fnStar){ref-type="table-fn"}Total cholesterol, mg/dL208.2(44.5)159.4(49.7)\<.001[\*](#tbl2fnStar){ref-type="table-fn"}209.1(50.0)178.7(51.2).037[\*](#tbl2fnStar){ref-type="table-fn"}HDL, mg/dL42.0(8.1)34.0(10.8)\<.001[\*](#tbl2fnStar){ref-type="table-fn"}8.1(8.8)39.7(10.9).004[\*](#tbl2fnStar){ref-type="table-fn"}LDL, mg/dL123.8(33.8)85.9(36.4)\<.001[\*](#tbl2fnStar){ref-type="table-fn"}116.4(33.6)104.5(40.1).263TG, mg/dL212.1(102.0)193.4(66.6).563223.6(141.6)169.1(93.6).122[^2][^3]

[Table 3](#t0015){ref-type="table"} demonstrates statistical significance of the differences in clinical and biochemical characteristics between Russian and Mexican study participants.Table 3Comparison of Russian and Mexican populations.Table 3VariableMenWomenHealthy, *p*CVD, *p*Healthy, *p*CVD, *p*Age, years.093.955.508.659BMI, kg/m^2^.001[\*](#tbl3fnStar){ref-type="table-fn"}.569.002[\*](#tbl3fnStar){ref-type="table-fn"}.118SBP, mm Hg.002[\*](#tbl3fnStar){ref-type="table-fn"}.001[\*](#tbl3fnStar){ref-type="table-fn"}.657.319DBP, mm Нg.021[\*](#tbl3fnStar){ref-type="table-fn"}.005[\*](#tbl3fnStar){ref-type="table-fn"}.055.256Smoking, %.001[\*](#tbl3fnStar){ref-type="table-fn"}\<.001[\*](#tbl3fnStar){ref-type="table-fn"}.056.089Diabetes, %.210.001[\*](#tbl3fnStar){ref-type="table-fn"}.026[\*](#tbl3fnStar){ref-type="table-fn"}.020[\*](#tbl3fnStar){ref-type="table-fn"}MI, %.009[\*](#tbl3fnStar){ref-type="table-fn"}.022[\*](#tbl3fnStar){ref-type="table-fn"}Total cholesterol, mg/dL.019[\*](#tbl3fnStar){ref-type="table-fn"}\<.001[\*](#tbl3fnStar){ref-type="table-fn"}.001[\*](#tbl3fnStar){ref-type="table-fn"}\<.001[\*](#tbl3fnStar){ref-type="table-fn"}HDL, mg/dL\<.001[\*](#tbl3fnStar){ref-type="table-fn"}\<.001[\*](#tbl3fnStar){ref-type="table-fn"}\<.001[\*](#tbl3fnStar){ref-type="table-fn"}\<.001[\*](#tbl3fnStar){ref-type="table-fn"}LDL, mg/dL.011[\*](#tbl3fnStar){ref-type="table-fn"}\<.001[\*](#tbl3fnStar){ref-type="table-fn"}\<.001[\*](#tbl3fnStar){ref-type="table-fn"}.009[\*](#tbl3fnStar){ref-type="table-fn"}TG, mg/dL\<.001[\*](#tbl3fnStar){ref-type="table-fn"}.396\<.001[\*](#tbl3fnStar){ref-type="table-fn"}.241[^4]

Mitochondrial heteroplasmy level in Russian and Mexican study participants is presented in [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}.Table 4Mitochondrial heteroplasmy level of Russian participants.Table 4Mitochondrial heteroplasmy, %MenWomenHealthyCVD*p*HealthyCVD*p*m.12315G\>A27.8(22.9)26.6(16.1).80332.4(15.7)34.0(15.0).777m.3256C\>T21.2(16.8)18.9(10.2).56122.2(12.3)23.5(14.8).770m.3336T\>C7.9(5.6)10.5(21.3).4527.8(7.9)8.5(3.5).762m.5178C\>A10.5(12.1)17.9(15.9).044[\*](#tbl4fnStar){ref-type="table-fn"}16.0(4.2)18.3(5.8).185m.13513G\>A27.8(24.6)31.0(21.4).61923.8(13.2)21.4(13.1).609m.14459G\>A38.5(26.7)31.9(26.9).36218.5(9.2)28.7(16.9).019[\*](#tbl4fnStar){ref-type="table-fn"}m.14846G\>A14.1(17.1)15.7(17.8).73116.5(19.8)13.1(4.8).575m.15059G\>A35.2(32.5)23.1(14.0).63636.3(13.1)43.7(11.0).106m.652insG28.6(22.5)26.8(19.3).75215.7(17.2)15.6(16.5).994m.1555A\>G17.4(16.4)17.2(9.5).95416.7(8.9)18.3(10.1).637[^5][^6]Table 5Mitochondrial heteroplasmy level of Mexican participants.Table 5Mitochondrial heteroplasmy, %MenWomenHealthyCVD*p*HealthyCVD*p*m.12315G\>A5.4(8.5)4.0(3.4).2602.7(2.6)2.7(1.8).998m.3256C\>T10.5(1.9)10.1(2.1).36410.4(1.9)9.4(1.7).043[\*](#tbl5fnStar){ref-type="table-fn"}m.3336T\>C2.6(0.8)1.7(0.5)\<.001[\*](#tbl5fnStar){ref-type="table-fn"}2.6(9.6)1.6(5.6)\<.001[\*](#tbl5fnStar){ref-type="table-fn"}m.5178C\>A10.3(27.7)1.7(0.8).017[\*](#tbl5fnStar){ref-type="table-fn"}1.6(6.8)7.6(20.7).122m.13513G\>A18.3(7.2)27.8(9.8)\<.001[\*](#tbl5fnStar){ref-type="table-fn"}20.0(6.6)23.2(7.2).098m.14459G\>A3.1(0.2)2.8(0.2)\<.001[\*](#tbl5fnStar){ref-type="table-fn"}3.2(2.5)2.7(0.2)\<.001[\*](#tbl5fnStar){ref-type="table-fn"}m.14846G\>A11.5(4.9)10.0(1.8).034[\*](#tbl5fnStar){ref-type="table-fn"}10.9(2.7)9.8(2.2).106m.15059G\>A3.1(0.6)3.6(1.5).0853.1(0.6)3.4(0.7).216m.652insG20.0(7.1)26.0(17.6)\<.001[\*](#tbl5fnStar){ref-type="table-fn"}21.1(7.3)27.5(7.4).003[\*](#tbl5fnStar){ref-type="table-fn"}m.1555A\>G30.0(43.6)12.1(5.8).002[\*](#tbl5fnStar){ref-type="table-fn"}15.7(7.9)21.8(29.2).285[^7][^8]

In samples from Russian population, heteroplasmy level of m.5178C\>A is significantly higher in male study participants with CVD than in healthy men; heteroplasmy level of m.14459G\>A prevails significantly in women with CVD.

In the sample from Mexican population, heteroplasmy level of m.13513G\>A and m.652insG prevails significantly in men with CVD, heteroplasmy level of m.3336T\>C, m.5178C\>A, m.14459G\>A, m.14846G\>A and m.1555A\>G are significantly higher in healthy men; m.652insG is significantly higher in female study participants with CVD, and m.3256C\>T, m.3336T\>C, m.14459G\>A -- in CVD-free women.

[Table 6](#t0030){ref-type="table"} demonstrates statistical significance of the difference of mitochondrial heteroplasmy level between Russian and Mexican study participants.Table 6Comparison of mitochondrial heteroplasmy level in Russian and Mexican study participants.Table 6Mitochondrial heteroplasmyMenWomenHealth, *p*CVD, *p*Health, *p*CVD, *p*m.12315G\>A\<.001[\*](#tbl6fnStar){ref-type="table-fn"}\<.001[\*](#tbl6fnStar){ref-type="table-fn"}\<.001[\*](#tbl6fnStar){ref-type="table-fn"}\<.001[\*](#tbl6fnStar){ref-type="table-fn"}m.3256C\>T.001[\*](#tbl6fnStar){ref-type="table-fn"}\<.001[\*](#tbl6fnStar){ref-type="table-fn"}\<.001[\*](#tbl6fnStar){ref-type="table-fn"}\<.001[\*](#tbl6fnStar){ref-type="table-fn"}m.3336T\>C\<.001[\*](#tbl6fnStar){ref-type="table-fn"}.002[\*](#tbl6fnStar){ref-type="table-fn"}.001[\*](#tbl6fnStar){ref-type="table-fn"}.010[\*](#tbl6fnStar){ref-type="table-fn"}m.5178C\>A.957\<.001[\*](#tbl6fnStar){ref-type="table-fn"}\<.001[\*](#tbl6fnStar){ref-type="table-fn"}.030[\*](#tbl6fnStar){ref-type="table-fn"}m.13513G\>A.037[\*](#tbl6fnStar){ref-type="table-fn"}.355.172.598m.14459G\>A\<.001[\*](#tbl6fnStar){ref-type="table-fn"}\<.001[\*](#tbl6fnStar){ref-type="table-fn"}\<.001[\*](#tbl6fnStar){ref-type="table-fn"}\<.001[\*](#tbl6fnStar){ref-type="table-fn"}m.14846G\>A.416.015[\*](#tbl6fnStar){ref-type="table-fn"}.137.009[\*](#tbl6fnStar){ref-type="table-fn"}m.15059G\>A\<.001[\*](#tbl6fnStar){ref-type="table-fn"}\<.001[\*](#tbl6fnStar){ref-type="table-fn"}\<.001[\*](#tbl6fnStar){ref-type="table-fn"}\<.001[\*](#tbl6fnStar){ref-type="table-fn"}m.652insG.040[\*](#tbl6fnStar){ref-type="table-fn"}.803.122.006[\*](#tbl6fnStar){ref-type="table-fn"}m.1555A\>G.081.006[\*](#tbl6fnStar){ref-type="table-fn"}.647.701[^9]

2. Experimental design, materials and methods {#s0010}
=============================================

Previously we have developed a quantitative assay of mutant allele measurement for mitochondrial heteroplasmic mutations [@bib1] and demonstrated significant differences between unaffected areas and atherosclerotic lesions in human aortic intima [@bib2]. Further the association of mitochondrial genetic variation with vascular diseases and carotid atherosclerosis has been demonstrated [@bib3], [@bib4], [@bib5], [@bib6].

In this study, the association of heteroplasmy level of mitochondrial mutations with CVD in Russian and Mexican populations was estimated. In total, 300 participants (150 in Russia, and 150 in Mexica) were included in the study. Men and women aged from 55 to 79 years (for women -- at least five years after menopause). Study participants were divided into CVD-free and CVD group by the results of cardiological examination. CVD group included patients who have been observed by a cardiologist with diagnosed CVD.

The observed levels of heteroplasmy did not reach the necessary level for the development of mitochondrial disorders in this study, since it is known that the level of mitochondrial heteroplasmy in patients should exceed 50% to evolve clinical manifestations [@bib7].

The study was conducted in accordance with the Helsinki Declaration of 1975 as revised in 1983; all participants gave their written informed consent prior to their inclusion in the study.

Mitochondrial DNA was isolated by phenol-chloroform extraction [@bib8]. Polymerase chain reaction (PCR) was used in order to obtain DNA fragments containing the region of the investigated mutations [@bib1]. Analysis of the heteroplasmy level was carried out in the investigated mutations using the original quantitative method previously developed on the basis of pyrosequencing technology [@bib9]. The level of heteroplasmy, i.e. % mutant copies of mtDNA from their total amount in the sample was estimated.

Statistical analysis was performed using the IBM SPSS 20.0 software (IBM Inc., USA). Data are expressed in terms of means and standard deviation.
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=============================================
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[^1]: Mean (SD) values are shown.

[^2]: Mean (SD) values are shown.

[^3]: Statistically significant difference at *p*\<.05.

[^4]: Statistically significant difference at *p*\<.05.

[^5]: Mean (SD) values are shown.

[^6]: Statistically significant difference at *p*\<.05.

[^7]: Mean (SD) values are shown.

[^8]: Statistically significant difference at *p*\<.05.

[^9]: Statistically significant difference at *p*\<.05.
